Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KDS-1000 for High-Risk Mild to Moderate COVID-19
NCT04797975Phase 2Withdrawn
- Sponsor
- Kiadis Pharma
- Start
- Dec 2020
- Primary completion
- Apr 2021
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
01
Overview
A Phase 2 trial of KDS-1000 in coronavirus disease 2019 (COVID-19), sponsored by Kiadis Pharma. Planned start Dec 2020; status: withdrawn.
02
Drugs
KDS-1000
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04797975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04797975.